Advertisement Kyowa submits additional indication application for penicillin formultions - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Kyowa submits additional indication application for penicillin formultions

Kyowa Hakko Kirin has submitted an additional indication application to Japan's Review Committee for the changes made in the maximum dosages of its synthesized penicillin - Pasetocin Capsules 125, Pasetocin Capsules 250, Pasetocin Fine Granules 10% and Pasetocin Tablets 250 to treat pediatric infectious diseases.

The changes were made based on a request from Ministry of Health, Labor and Welfare for development of new dosages of Pasetocin.

Pasetocin is a broad spectrum antibiotic that, when administered in higher doses, promises to be effective against various bacterial strains.

The company claims as such, having also considered factors such as the approval status of the medicine overseas, we have filed application regarding a change in the maximum daily applied dose with respect to indicated strains and indications that have already been approved.